Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Drugs
Erschienen in: Drugs 7/2014

01.05.2014 | Adis Drug Evaluation

Sevelamer Carbonate: A Review in Hyperphosphataemia in Adults with Chronic Kidney Disease

verfasst von: Caroline M. Perry, Greg L. Plosker

Erschienen in: Drugs | Ausgabe 7/2014

Einloggen, um Zugang zu erhalten

Abstract

Sevelamer carbonate (Renvela®), a buffered form of sevelamer hydrochloride (Renagel®), is an orally administered non-absorbed phosphate-binding anion exchange resin used in the treatment of hyperphosphataemia in chronic kidney disease (CKD). In the EU, sevelamer carbonate is approved in adult CKD patients who require dialysis and in those who do not require dialysis with serum phosphate levels ≥1.78 mmol/L, whereas in the USA sevelamer carbonate is approved in adult CKD patients who require dialysis. Sevelamer carbonate and sevelamer hydrochloride achieved similar reductions in serum phosphate levels in randomized comparative trials in patients with CKD receiving haemodialysis; sevelamer carbonate also reduced serum phosphate levels in noncomparative studies in CKD patients not requiring dialysis. The most common adverse events with sevelamer carbonate are gastrointestinal in nature. Sevelamer has pleiotropic effects, such as improving the serum lipid profile and attenuating endothelial and cardiovascular risk factors in CKD. All formulations of sevelamer have markedly higher acquisition costs than calcium-based phosphate binders. Cost-effectiveness analyses focusing specifically on sevelamer carbonate have not been conducted, and those based on clinical trial data with sevelamer hydrochloride have provided both favourable and unfavourable results compared with calcium-based phosphate binders, reflecting heterogeneity between modelled analyses in terms of data sources, assumptions, comparators, geographical regions, type of costs included and other factors. Although well-designed studies evaluating the impact of phosphate binders on hard clinical endpoints appear to be warranted, sevelamer carbonate may be particularly useful for the treatment of patients at risk of metabolic acidosis (offering advantages over sevelamer hydrochloride in this regard) and for individuals requiring treatment with a phosphate binding agent that does not contain aluminium or calcium.
Literatur
1.
2.
Kidney Disease Improving Global Outcomes (KDIGO). KDIGO Clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Inter. 2009;76(Suppl 113):S1–S130.
3.
Sprague SM. A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate. Curr Med Res Opin. 2007;23(12):3167–75.PubMedCrossRef
4.
Martin P, Wang P, Robinson A, et al. Comparison of dietary phosphate absorption after single doses of lanthanum carbonate and sevelamer carbonate in healthy volunteers: a balance study. Am J Kidney Dis. 2011;57(5):700–6.PubMedCrossRef
5.
Di Iorio B, Bellasi A, Russo D. Mortality in kidney disease patients treated with phosphate binders: a randomized study [Erratum appears in Clin J Am Soc Nephrol. 2012 Aug, 7(8), pp. 1370–1]. Clin J Am Soc Nephrol. 2012;7(3):487–93.PubMedCrossRef
6.
National Kidney Foundation. Treatment guidelines K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42(Suppl. 3(4)):S1–201.
7.
Yamada K, Fujimoto S, Tokura T, et al. Effect of sevelamer on dyslipidemia and chronic inflammation in maintenance hemodialysis patients. Ren Fail. 2005;27(4):361–5.PubMedCrossRef
8.
Kidney Disease Improving Global Outcomes (KDIGO). KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Inter Suppl. 2013;3(4):1–150.
9.
10.
Goldsmith DR, Scott LJ, Cvetkovic RS, et al. Sevelamer hydrochloride: a review of its use for hyperphosphataemia in patients with end-stage renal disease on haemodialysis. Drugs. 2008;68(1):85–104.PubMedCrossRef
11.
Tonelli M, Wiebe N, Culleton B, et al. Systematic review of the clinical efficacy and safety of sevelamer in dialysis patients. Nephrol Dial Transplant. 2007;22(10):2856–66.PubMedCrossRef
12.
Delmez J, Block G, Robertson J, et al. A randomized, double-blind, crossover design study of sevelamer hydrochloride and sevelamer carbonate in patients on hemodialysis. Clin Nephrol. 2007;68(6):386–91.PubMedCrossRef
13.
Fan S, Ross C, Mitra S, et al. A randomized, crossover design study of sevelamer carbonate powder and sevelamer hydrochloride tablets in chronic kidney disease patients on haemodialysis. Nephrol Dial Transplant. 2009;24(12):3794–9.PubMedCentralPubMedCrossRef
14.
Pai AB, Shepler BM. Comparison of sevelamer hydrochloride and sevelamer carbonate: risk of metabolic acidosis and clinical implications. Pharmacotherapy. 2009;29(5):554–61.PubMedCrossRef
15.
Oka Y, Miyazaki M, Takatsu S, et al. Sevelamer hydrochloride exacerbates metabolic acidosis in hemodialysis patients, depending on the dosage. Ther Apher Dial. 2007;11(2):107–13.PubMedCrossRef
16.
De Santo NG, Frangiosa A, Anastasio P, et al. Sevelamer worsens metabolic acidosis in hemodialysis patients. J Nephrol. 2006;19(Suppl. 9):S108–14.PubMed
17.
Vlahakos DV, Retsa K, Kalogeropoulou S, et al. Chronic acid-base perturbations in hemodialysis patients treated with sevelamer hydrochloride: a two-year follow-up study. Artif Organs. 2007;31(12):892–5.PubMedCrossRef
18.
19.
20.
Ikee R, Tsunoda M, Sasaki N, et al. Emerging effects of sevelamer in chronic kidney disease. Kidney Blood Press Res. 2013;37(1):24–32.PubMedCrossRef
21.
Lin Y-F, Chien C-T, Kan W-C, et al. Pleiotropic effects of sevelamer beyond phosphate binding in end-stage renal disease patients: a randomized, open-label, parallel-group study. Clin Drug Invest. 2011;31(4):257–67.CrossRef
22.
Rastogi A. Sevelamer revisited: pleiotropic effects on endothelial and cardiovascular risk factors in chronic kidney disease and end-stage renal disease. Ther Adv Cardiovasc Dis. 2013;7(6):322–42.PubMedCentralPubMedCrossRef
23.
Fishbane S, Delmez J, Suki WN, et al. A randomized, parallel, open-label study to compare once-daily sevelamer carbonate powder dosing with thrice-daily sevelamer hydrochloride tablet dosing in CKD patients on hemodialysis. Am J Kidney Dis. 2010;55(2):307–15.PubMedCrossRef
24.
Abraham G, Kher V, Saxena S, et al. Sevelamer carbonate experience in Indian end stage renal disease patients. Indian J Nephrol. 2012;22(3):189–92.PubMedCentralPubMedCrossRef
25.
Chen N, Wu X, Ding X, et al. Sevelamer carbonate lowers serum phosphorus effectively in haemodialysis patients: a randomized, double-blind, placebo-controlled, dose-titration study. Nephrol Dial Transplant. 2014;29:152–60.PubMedCrossRef
26.
Ketteler M, Rix M, Fan S, et al. Efficacy and tolerability of sevelamer carbonate in hyperphosphatemic patients who have chronic kidney disease and are not on dialysis. Clin J Am Soc Nephrol. 2008;3(4):1125–30.PubMedCentralPubMedCrossRef
27.
Bezzaoucha S, Pichette V, Lafrance JP, et al. The role of sevelamer carbonate in increasing serum bicarbonate in hyperphosphatemic predialysis patients who have metabolic acidosis. Int J Clin Pharmacol Ther. 2013;51(12):989–90.PubMedCrossRef
28.
Takei T, Otsubo S, Uchida K, et al. Effects of sevelamer on the progression of vascular calcification in patients on chronic haemodialysis. Nephron Clin Pract. 2008;108(4):c278–83.PubMedCrossRef
29.
Yilmaz MI, Sonmez A, Saglam M, et al. Comparison of calcium acetate and sevelamer on vascular function and fibroblast growth factor 23 in CKD patients: a randomized clinical trial. Am J Kidney Dis. 2012;59(2):177–85.PubMedCrossRef
30.
Almirall J, Lopez T, Vallve M, et al. Safety and efficacy of sevelamer in the treatment of uncontrolled hyperphosphataemia of haemodialysis patients. Nephron Clin Pract. 2004;97(1):c17–22.PubMedCrossRef
31.
Liu Y-L, Lin H-H, Yu C-C, et al. A comparison of sevelamer hydrochloride with calcium acetate on biomarkers of bone turnover in hemodialysis patients. Ren Fail. 2006;28(8):701–7.PubMedCrossRef
32.
Iwasaki Y, Takami H, Tani M, et al. Efficacy of combined sevelamer and calcium carbonate therapy for hyperphosphatemia in Japanese hemodialysis patients. Therap Apher Dial. 2005;9(4):347–51.CrossRef
33.
Slatopolsky EA, Burke SK, Dillon MA, et al. RenaGel, a nonabsorbed calcium- and aluminium-free phosphate binder, lowers serum phosphorus and parathyroid hormone. Kidney Int. 1999;55(1):299–307.PubMedCrossRef
34.
Ishida M, Yao N, Yachiku S, et al. Management of calcium, phosphorus and bone metabolism in dialysis patients using sevelamer hydrochloride and vitamin D therapy. Ther Apher Dial. 2005;9(Suppl. 1):S16–21.PubMedCrossRef
35.
Koiwa F, Onoda N, Kato H, et al. Prospective randomized multicenter trial of sevelamer hydrochloride and calcium carbonate for the treatment of hyperphosphatemia in hemodialysis patients in Japan. Therap Apher Dial. 2005;9(4):340–6.CrossRef
36.
Kokuho T, Toya Y, Kawaguchi Y, et al. Sevelamer hydrochloride improves hyperphosphatemia in hemodialysis patients with low bone turnover rate and low intact parathyroid hormone levels. Therap Apher Dial. 2007;11(6):442–8.CrossRef
37.
Spatz C, Roe K, Lehman E, et al. Effect of a non-calcium-based phosphate binder on fibroblast growth factor 23 in chronic kidney disease. Nephron Clin Pract. 2013;123(1–2):61–6.PubMedCrossRef
38.
Kasai S, Sato K, Murata Y, et al. Randomized crossover study of the efficacy and safety of sevelamer hydrochloride and lanthanum carbonate in Japanese patients undergoing hemodialysis. Ther Apher Dial. 2012;16(4):341–9.PubMedCrossRef
39.
Chertow GM, Raggi P, McCarthy JT, et al. The effects of sevelamer and calcium acetate on proxies of atherosclerotic and arteriosclerotic vascular disease in hemodialysis patients. Am J Nephrol. 2003;23(5):307–14.PubMedCrossRef
40.
Inoue T, Nagatoya K, Kagitani M, et al. Influence of sevelamer on mineral metabolism and hyperparathyroidism in Japanese hemodialysis patients. Ther Apher Dial. 2007;11(3):210–4.PubMedCrossRef
41.
Ohno I, Yamaguchi Y, Saikawa H, et al. Sevelamer decreases serum uric acid concentration through adsorption of uric acid in maintenance hemodialysis patients. Intern Med. 2009;48(6):415–20.PubMedCrossRef
42.
Braun J, Asmus HG, Holzer H, et al. Long-term comparison of a calcium-free phosphate binder and calcium carbonate–phosphorus metabolism and cardiovascular calcification. Clin Nephrol. 2004;62(2):104–15.PubMedCrossRef
43.
Wesseling-Perry K, Harkins GC, Wang H-J, et al. Response of different PTH assays to therapy with sevelamer or CaCO3 and active vitamin D sterols. Pediatr Nephrol. 2009;24(7):1355–61.PubMedCentralPubMedCrossRef
44.
Hamida FB, Fatma LB, Barbouch S, et al. Effect of sevelamer on mineral and lipid abnormalities in hemodialysis patients. Saudi J Kidney Dis Transpl. 2008;19(2):183–8.PubMed
45.
Lin Y-F, Chen Y-M, Hung K-Y, et al. Benefits of sevelamer on markers of bone turnover in Taiwanese hemodialysis patients. J Formos Med Assoc. 2010;109(9):663–72.PubMedCrossRef
46.
Barreto DV, Barreto FDC, De Carvalho AB, et al. Phosphate binder impact on bone remodeling and coronary calcification - results from the BRiC study. Nephron Clin Pract. 2008;110(4):c273–83.PubMedCrossRef
47.
Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. 2002;62(1):245–52.PubMedCrossRef
48.
Ibrahim FH, Fadhlina NZ, Ng EK, et al. A randomized, open-label, crossover design study to compare the safety and efficacy of sevelamer carbonate versus calcium carbonate in the treatment of hyperphosphataemia in patients with chronic kidney disease on dialysis [abstract no. MP548]. Nephrol Dial Transplant. 2013;28(Suppl. 1):i470.
49.
Caglar K, Yilmaz MI, Saglam M, et al. Short-term treatment with sevelamer increases serum fetuin-a concentration and improves endothelial dysfunction in chronic kidney disease stage 4 patients. Clin J Am Soc Nephrol. 2008;3(1):61–8.PubMedCentralPubMedCrossRef
50.
Bleskestad IH, Bergrem H, Hartmann A, et al. Fibroblast growth factor 23 and parathyroid hormone after treatment with active vitamin D and sevelamer carbonate in patients with chronic kidney disease stage 3b, a randomized crossover trial. BMC Nephrol. 2012;13:49.PubMedCentralPubMedCrossRef
51.
Chudek J, Piecha G, Kokot F, et al. Influence of sevelamer hydrochloride on serum concentration of whole (1-84) and N-terminally truncated (7-84) parathyroid hormone fragments in hemodialysis uremic patients. J Nephrol. 2003;16(5):710–5.PubMed
52.
Braunlin W, Zhorov E, Guo A, et al. Bile acid binding to sevelamer HCl. Kidney Int. 2002;62(2):611–9.PubMedCrossRef
53.
Shantouf R, Budoff MJ, Ahmadi N, et al. Effects of sevelamer and calcium-based phosphate binders on lipid and inflammatory markers in hemodialysis patients. Am J Nephrol. 2008;28(2):275–9.PubMedCentralPubMedCrossRef
54.
Iimori S, Mori Y, Akita W, et al. Effects of sevelamer hydrochloride on mortality, lipid abnormality and arterial stiffness in hemodialyzed patients: a propensity-matched observational study. Clin Exp Nephrol. 2012;16(6):930–7.PubMedCrossRef
55.
Boaz M, Katzir Z, Schwartz D, et al. Effect of sevelamer hydrochloride exposure on carotid intima media thickness in hemodialysis patients. Nephron Clin Pract. 2011;117(2):c83–8.PubMedCrossRef
56.
Ferramosca E, Burke S, Chasan-Taber S, et al. Potential antiatherogenic and anti-inflammatory properties of sevelamer in maintenance hemodialysis patients. Am Heart J. 2005;149(5):820–5.PubMedCrossRef
57.
Vlassara H, Uribarri J, Cai W, et al. Effects of sevelamer on HbA1c, inflammation, and advanced glycation end products in diabetic kidney disease. Clin J Am Soc Nephrol. 2012;7(6):934–42.PubMedCentralPubMedCrossRef
58.
Hervas JG, Prados D, Cerezo S. Treatment of hyperphosphatemia with sevelamer hydrochloride in hemodialysis patients: a comparison with calcium acetate. Kidney Int Suppl. 2003;85:S69–72.PubMedCrossRef
59.
Ferreira A, Frazao JM, Monier-Faugere MC, et al. Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients. J Am Soc Nephrol. 2008;19(2):405–12.PubMedCentralPubMedCrossRef
60.
Qunibi W, Moustafa M, Muenz LR, et al. A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study. Am J Kidney Dis. 2008;51(6):952–65.PubMedCrossRef
61.
Chennasamudram SP, Noor T, Vasylyeva TL. Comparison of sevelamer and calcium carbonate on endothelial function and inflammation in patients on peritoneal dialysis. J Ren Care. 2013;39(2):82–9.PubMedCrossRef
62.
63.
Brandenburg VM, Schlieper G, Heussen N, et al. Serological cardiovascular and mortality risk predictors in dialysis patients receiving sevelamer: a prospective study. Nephrol Dial Transplant. 2010;25(8):2672–9.PubMedCrossRef
64.
Kakuta T, Tanaka R, Hyodo T, et al. Effect of sevelamer and calcium-based phosphate binders on coronary artery calcification and accumulation of circulating advanced glycation end products in hemodialysis patients. Am J Kidney Dis. 2011;57(3):422–31.PubMedCrossRef
65.
Raggi P, Bommer J, Chertow GM. Valvular calcification in hemodialysis patients randomized to calcium-based phosphorus binders or sevelamer. J Heart Valve Dis. 2004;13(1):134–41.PubMed
66.
Izumi M, Morita S, Nishian Y, et al. Switching from calcium carbonate to sevelamer hydrochloride has suppressive effects on the progression of aortic calcification in hemodialysis patients: assessment using plain chest X-ray films. Ren Fail. 2008;30(10):952–8.PubMedCrossRef
67.
Block GA, Spiegel DM, Ehrlich J, et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int. 2005;68(4):1815–24.PubMedCrossRef
68.
Russo D, Miranda I, Ruocco C, et al. The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer. Kidney Int. 2007;72(10):1255–61.PubMedCrossRef
69.
Di Lullo L, Floccari F, Santoboni A, et al. Progression of cardiac valve calcification and decline of renal function in CKD patients. J Nephrol. 2013;26(4):739–44.PubMedCrossRef
70.
Veighey K, Booth J, Davenport A. Does the choice of phosphate binder affect trace element levels in chronic kidney disease patients treated by regular haemodialysis? Nephrol Dial Transplant. 2011;26(3):1006–10.PubMedCrossRef
71.
Iwata Y, Wada T, Yokoyama H, et al. Effect of sevelamer hydrochloride on markers of bone turnover in Japanese dialysis patients with low biointact PTH levels. Intern Med. 2007;46(8):447–52.PubMedCrossRef
72.
Covic A, Passlick-Deetjen J, Kroczak M, et al. A comparison of calcium acetate/magnesium carbonate and sevelamer-hydrochloride effects on fibroblast growth factor-23 and bone markers: post hoc evaluation from a controlled, randomized study. Nephrol Dial Transplant. 2013;28(9):2383–92.PubMedCentralPubMedCrossRef
73.
Oliveira RB, Cancela ALE, Graciolli FG, et al. Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy? Clin J Am Soc Nephrol. 2010;5(2):286–91.PubMedCentralPubMedCrossRef
74.
de Oliveira RB, Graciolli FG, dos Reis LM, et al. Disturbances of Wnt/beta-catenin pathway and energy metabolism in early CKD: effect of phosphate binders. Nephrol Dial Transplant. 2013;28(10):2510–7.PubMedCrossRef
75.
Raggi P, James G, Burke SK, et al. Decrease in thoracic vertebral bone attenuation with calcium-based phosphate binders in hemodialysis. J Bone Miner Res. 2005;20(5):764–72.PubMedCrossRef
76.
Boaz M, Chernin G, Schwartz I, et al. C-reactive protein and carotid and femoral intima media thickness: predicting inflammation. Clin Nephrol. 2013;80:449–55.PubMedCrossRef
77.
Stinghen AEM, Goncalves SM, Bucharles S, et al. Sevelamer decreases systemic inflammation in parallel to a reduction in endotoxemia. Blood Purif. 2010;29(4):352–6.PubMedCrossRef
78.
Guida B, Cataldi M, Riccio E, et al. Plasma p-cresol lowering effect of sevelamer in peritoneal dialysis patients: evidence from a cross-sectional observational study. PLoS One. 2013;8(8):e73558.PubMedCentralPubMedCrossRef
79.
Garg JP, Chasan-Taber S, Blair A, et al. Effects of sevelamer and calcium-based phosphate binders on uric acid concentrations in patients undergoing hemodialysis: a randomized clinical trial. Arthritis Rheum. 2005;52(1):290–5.PubMedCrossRef
80.
Ikee R, Tsunoda M, Sasaki N, et al. Potential influence of sevelamer hydrochloride on responsiveness to erythropoiesis-stimulating agents in haemodialysis patients. Nephrology. 2012;17(3):225–9.PubMedCrossRef
81.
Sun PP, Perianayagam MC, Jaber BL. Sevelamer hydrochloride use and circulating endotoxin in hemodialysis patients: a pilot cross-sectional study. J Ren Nutr. 2009;19(5):432–8.PubMedCrossRef
82.
Navarro-Gonzalez JF, Mora-Fernandez C, Muros de Fuentes M, et al. Effect of phosphate binders on serum inflammatory profile, soluble CD14, and endotoxin levels in hemodialysis patients. Clin J Am Soc Nephrol. 2011;6(9):2272–9.
83.
Thomsen S. Delayed progression to dialysis with early and intensive management of predialysis chronic kidney disease: a case-based approach. Case Rep Nephrol Urol. 2013;3:74–86.PubMedCentralPubMedCrossRef
84.
Mathew S, Lund RJ, Strebeck F, et al. Reversal of the adynamic bone disorder and decreased vascular calcification in chronic kidney disease by sevelamer carbonate therapy. J Am Soc Nephrol. 2007;18(1):122–30.PubMedCrossRef
85.
Maizel J, Six I, Dupont S, et al. Effects of sevelamer treatment on cardiovascular abnormalities in mice with chronic renal failure. Kidney Int. 2013;84(3):491–500.PubMedCrossRef
86.
Hauser AB, Azevedo IR, Goncalves S, et al. Sevelamer carbonate reduces inflammation and endotoxemia in an animal model of uremia. Blood Purif. 2010;30(3):153–8.PubMedCrossRef
87.
Tokumoto M, Mizobuchi M, Finch JL, et al. Blockage of the renin-angiotensin system attenuates mortality but not vascular calcification in uremic rats: sevelamer carbonate prevents vascular calcification. Am J Nephrol. 2009;29(6):582–91.PubMedCrossRef
88.
Plone MA, Petersen JS, Rosenbaum DP, et al. Sevelamer, a phosphate-binding polymer, is a non-absorbed compound. Clin Pharmacokinet. 2002;41(7):517–23.PubMedCrossRef
89.
Kays MB, Overholser BR, Mueller BA, et al. Effects of sevelamer hydrochloride and calcium acetate on the oral bioavailability of ciprofloxacin. Am J Kidney Dis. 2003;42(6):1253–9.PubMedCrossRef
90.
Guillen-Anaya MA, Jadoul M. Drug interaction between sevelamer and cyclosporin [letter]. Nephrol Dial Transplant. 2004;19(2):515.PubMedCrossRef
91.
Pieper AK, Buhle F, Bauer S, et al. The effect of sevelamer on the pharmacokinetics of cyclosporin A and mycophenolate mofetil after renal transplantation. Nephrol Dial Transplant. 2004;19(10):2630–3.PubMedCrossRef
92.
Pierce D, Hossack S, Poole L, et al. The effect of sevelamer carbonate and lanthanum carbonate on the pharmacokinetics of oral calcitriol. Nephrol Dial Transplant. 2011;26(5):1615–21.PubMedCentralPubMedCrossRef
93.
Genzyme. Post authorisation safety study of Renvela in chronic kidney disease patients not on dialysis with hyperphosphataemia [ClinicalTrials.gov identifier NCT01857024]. US National Institutes of Health. ClinicalTrials.gov. 2014. http://​clinicaltrials.​gov/​ct2/​show/​NCT01857024. Accessed 18 Mar 2014.
94.
Bernard L, Mendelssohn D, Dunn E, et al. A modeled economic evaluation of sevelamer for treatment of hyperphosphatemia associated with chronic kidney disease among patients on dialysis in the United Kingdom. J Med Econ. 2013;16(1):1–9.PubMedCrossRef
95.
Thompson M, Bartko-Winters S, Bernard L, et al. Economic evaluation of sevelamer for the treatment of hyperphosphatemia in chronic kidney disease patients not on dialysis in the United Kingdom. J Med Econ. 2013;16(6):744–55.PubMedCrossRef
96.
Manns B, Klarenbach S, Lee H, et al. Economic evaluation of sevelamer in patients with end-stage renal disease. Nephrol Dial Transplant. 2007;22(10):2867–78.PubMedCrossRef
97.
Taylor MJ, Elgazzar HA, Chaplin S, et al. An economic evaluation of sevelamer in patients new to dialysis. Curr Med Res Opin. 2008;24(2):601–8.PubMedCrossRef
98.
Huybrechts KF, Caro JJ, O’Brien JA. Prevention and management of hyperphosphatemia with sevelamer in Canada: health and economic consequences. Value Health. 2009;12(1):16–9.PubMedCrossRef
99.
Huybrechts KF, Caro JJ, Wilson DA, et al. Health and economic consequences of sevelamer use for hyperphosphatemia in patients on hemodialysis. Value Health. 2005;8(5):549–61.PubMedCrossRef
100.
Pharmaceutical Press. British National Formulary. 67th ed. UK: Basingstoke; 2014.
101.
St. Peter WL, Fan Q, Weinhandl E, et al. Economic evaluation of sevelamer versus calcium-based phosphate binders in hemodialysis patients: a secondary analysis using centers for Medicare & Medicaid services data. Clin J Am Soc Nephrol. 2009;4(12):1954–61.
102.
Suki WN, Zabaneh R, Cangiano JL, et al. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int. 2007;72(9):1130–7.PubMedCrossRef
103.
St. Peter WL, Liu J, Weinhandl E, et al. A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data. Am J Kidney Dis. 2008;51(3):445–54.
104.
Collins AJ, St. Peter WL, Dalleska FW, et al. Hospitalization risks between Renagel phosphate binder treated and non-Renagel treated patients. Clin Nephrol. 2000;54(4):334–41.
105.
Hanus M, Zhorov E, Brommage D, et al. Assessment of phosphate binding by sevelamer carbonate powder for oral suspension mixed in foods. Nephrol Nurs J. 2012;39(3):239–43, 55.
106.
107.
108.
Ritz E. The clinical management of hyperphosphatemia. J Nephrol. 2005;18(3):221–8.PubMed
109.
110.
Locatelli F, Dimkovic N, Spasovski G. Evaluation of colestilan in chronic kidney disease dialysis patients with hyperphosphataemia and dyslipidaemia: a randomized, placebo-controlled, multiple fixed-dose trial. Nephrol Dial Transplant. 2013;28(7):1874–88.PubMedCrossRef
111.
112.
113.
114.
Gonzalez E, Schomberg J, Amin N, et al. Sevelamer carbonate increases serum bicarbonate in pediatric dialysis patients. Pediatr Nephrol. 2010;25(2):373–5.PubMedCrossRef
115.
Mahdavi H, Kuizon BD, Gales B, et al. Sevelamer hydrochloride: an effective phosphate binder in dialyzed children. Pediatr Nephrol. 2003;18(12):1260–4.PubMedCrossRef
116.
Storms LE, Chicella MF, Dice JE. Sevelamer therapy for pediatric end-stage renal disease. Pharmacotherapy. 2006;26(3):410–3.PubMedCrossRef
117.
Abdullah S, Diezi M, Sung L, et al. Sevelamer hydrochloride: a novel treatment of hyperphosphatemia associated with tumor lysis syndrome in children. Pediatr Blood Cancer. 2008;51(1):59–61.PubMedCrossRef
118.
Gulati A, Sridhar V, Bose T, et al. Short-term efficacy of sevelamer versus calcium acetate in patients with chronic kidney disease stage 3–4. Int Urol Nephrol. 2010;42(4):1055–62.PubMedCrossRef
119.
Pieper A-K, Haffner D, Hoppe B, et al. A randomized crossover trial comparing sevelamer with calcium acetate in children with CKD. Am J Kidney Dis. 2006;47(4):625–35.PubMedCrossRef
120.
Di Iorio B, Molony D, Bell C, et al. Sevelamer versus calcium carbonate in incident hemodialysis patients: results of an open-label 24-month randomized clinical trial. Am J Kidney Dis. 2013;62(4):771–8.PubMedCrossRef
121.
Jamal SA, Fitchett D, Lok CE, et al. The effects of calcium-based versus non-calcium-based phosphate binders on mortality among patients with chronic kidney disease: a meta-analysis. Nephrol Dial Transplant. 2009;24(10):3168–74.PubMedCrossRef
122.
Jamal SA, Vandermeer B, Raggi P, et al. Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis. Lancet. 2013;382(9900):1268–77.PubMedCrossRef
123.
Block GA, Raggi P, Bellasi A, et al. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int. 2007;71(5):438–41.PubMedCrossRef
124.
Borzecki AM, Lee A, Wang SW, et al. Survival in end stage renal disease: calcium carbonate vs. sevelamer. J Clin Pharm Ther. 2007;32(6):617–24.PubMedCrossRef
125.
Panichi V, Bigazzi R, Paoletti S, et al. Impact of calcium, phosphate, PTH abnormalities and management on mortality in hemodialysis: results from the RISCAVID study. J Nephrol. 2010;23(5):556–62.PubMed
126.
Di Iorio B, Bellasi A, Russo D, et al. Mortality in kidney disease patients treated with phosphate binders: a randomized study [Erratum appears in Clin J Am Soc Nephrol. 2012 Aug, 7(8), pp. 1370–1]. Clin J Am Soc Nephrol. 2012;7(3):487–93.PubMedCrossRef
127.
Russo D, Bellasi A, Pota A, et al. Effects of phosphorus-restricted diet and phosphate-binding therapy on outcomes in patients with chronic kidney disease. J Nephrol. 2014. doi:10.​1007/​s40620-014-0071-2
128.
Yusuf AA, Weinhandl ED, St Peter WL. Comparative effectiveness of calcium acetate and sevelamer on clinical outcomes in elderly hemodialysis patients enrolled in Medicare part D. Am J Kidney Dis. 2013. doi:10.​1053/​j.​ajkd.​2013.​11.​015
129.
Metadaten
Titel
Sevelamer Carbonate: A Review in Hyperphosphataemia in Adults with Chronic Kidney Disease
verfasst von
Caroline M. Perry
Greg L. Plosker
Publikationsdatum
01.05.2014
Verlag
Springer International Publishing
Erschienen in
Drugs / Ausgabe 7/2014
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-014-0215-7

Weitere Artikel der Ausgabe 7/2014

Drugs 7/2014 Zur Ausgabe

Review Article

Management of Asthma and Chronic Obstructive Pulmonary Disease with Combination Inhaled Corticosteroids and Long-Acting β-Agonists: A Review of Comparative Effectiveness Research

Review Article

Advances in the Diagnosis and Therapeutic Management of Atopic Dermatitis

R&D Insight Report

Apremilast: First Global Approval

Current Opinion

Defining Phenotypes in Asthma: A Step Towards Personalized Medicine

Leading Article

Serotonergic Therapies for Cognitive Symptoms in Alzheimer’s Disease: Rationale and Current Status

Adis Drug Evaluation

Canagliflozin: A Review of Its Use in Patients with Type 2 Diabetes Mellitus